Evozyne has closed an $81 million Series B investment round that will fund the biotech’s generative AI-powered drug discovery platform and product development. “In its first three years, Evozyne proved it could deliver novel, high-performance proteins that solve critical problems in healthcare and sustainability. Our next three years will be tightly focused on maximising our […]
